PDCD1 and neoplasm: Blocking the PD-1 signaling pathway reactivates the synthetic metabolism of ExTs and enhances glucose uptake in a mammalian target of rapamycin-dependent manner, which may contribute to the improvement of tumor-infiltrating lymphocyte function and tumor regression [30].